BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//TrialSonar//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:TrialSonar · $JAZZ readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by TrialSonar. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06695845-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Zanidatamab readout (P2) · Jazz Pharmaceuticals $JAZZ
DESCRIPTION:A Phase 2 Study of Zanidatamab in Patients With HER2-expressing
  Tumors\n\nPrimary completion date: 2026-12-31 (estimated)\nPhase 2 · Onc
 ology · Breast Cancer\, Gastric Cancer\, Esophageal Cancer\nEnrollment: 2
 00 · Sites: 42\n\nPrimary completion = last participant's primary-endpoin
 t data collected\; topline results usually follow weeks to months later. S
 ponsor-reported\, often an estimate. Not investment advice.\n\nhttps://tri
 alsonar.netlify.app/radar.html?nct=NCT06695845\nhttps://clinicaltrials.gov
 /study/NCT06695845
URL:https://datacutoff.com/radar.html?nct=NCT06695845
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
